AB 011
Alternative Names: AB-011Latest Information Update: 28 Apr 2025
At a glance
- Originator CARsgen
 - Class Antineoplastics; Immunotherapies; Monoclonal antibodies
 - Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- No development reported Gastric cancer; Pancreatic cancer; Solid tumours
 
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours in China (Parenteral)
 - 28 Jul 2023 No recent reports of development identified for phase-I development in Gastric-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral, Injection)
 - 28 Jul 2023 No recent reports of development identified for phase-I development in Gastric-cancer(Late-stage disease, Monotherapy, Second-line therapy or greater) in China (Parenteral, Injection)